Acumen Pharmaceuticals, Inc.

Submit an IND filing for a lead clinical candidate in the Enhanced Brain Delivery program

Deadline not yet reached (246 days left)

Announced: 26 Oct 2026
Due: 30 Jun 2027

Deadline
Met
Late
Not met
Today

What the company said

“The Company is targeting the submission of an IND filing with respect to a lead clinical candidate in its EBD program in mid-2027.”

SourceAcumen Pharmaceuticals, Inc. Form 8-K press release, 2026-10-26
FilingSEC filing index
Deadline as statedin mid-2027
Deadline used30 Jun 2027, the last day of the stated period
TypeRegulatory
Permanent referenceKI-C-2026-ABOS-025281
Cite as https://keptindex.org/c/KI-C-2026-ABOS-025281/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 30 Jun 2027.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Regulatory filing
Indicative materiality: Medium rules
Action: Submit
Deliverable: IND filing for lead Enhanced Brain Delivery candidate
Language: Aspirational (“aims”, “intends”)
In the company’s control: High
Specificity: Medium
Depends on: Regulatory

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Acumen Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-ABOS-025281 · Corrections policy